BioSpace News Archive

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the three- and twelve-month periods ended December 31, 2020 on Thursday, March 18,

ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of cancer.

Austhera BioSciences, Inc. today announced that Edward Rudnic, CEO and David Snyder, CFO will present an overview of the company at the upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on March 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering an aggregate of 3,500 shares of Puma common stock to one new non-executive employee.

Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (“Miravo” or “the Company”) a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that it has filed a preliminary base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada (the “Prospectus”).

Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 9, 2021 at 12:00 PM EST (11:00 AM CST, 10:00 AM MST)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences

“We are delighted to collaborate with Lonza recognizing their team of experts who will lead the process development and GMP manufacture of Ixovex-1, a highly potent next-generation, tumor-selective oncolytic virus that can be used in a wide variety of solid tumors”.

On Feb. 26th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as “Winhealth Pharma”) signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as “Merz”).